Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.


In addition to our HBV Assets, we are developing a pipeline of Oncology, Anti-viral and Metabolic Programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.

View all »   RSSRecent Releases

Nov 5, 2015
Arbutus Biopharma Announces Third Quarter 2015 Financial Results

Oct 28, 2015
Arbutus Provides an HBV Pipeline Update

View all »Events & Presentations

Nov 18, 2015 at 8:45 AM ET
Stifel 2015 Healthcare Conference

Nov 17, 2015
AASLD Conference